Literature DB >> 4796621

Active management of severe pre-eclampsia.

T F Baskett, C R Bradford.   

Abstract

An active approach to the management of severe pre-eclampsia is outlined using sedation with diazepam, hypotensive therapy with hydralazine and immediate steps to terminate the pregnancy.Clinical experience with 80 cases is described. There was no maternal loss and corrected perinatal mortality was 4.8%.

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4796621      PMCID： PMC1947082     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN： 0008-4409            Impact factor:   8.262


  7 in total

1.  Foetal salvage in early severe toxaemias of pregnancy.

Authors:  G MAIZELS
Journal:  S Afr Med J       Date:  1958-05-10

2.  Use of benzodiazepines in the management of eclampsia.

Authors:  T H Lean; S S Ratnam; R Sivasamboo
Journal:  J Obstet Gynaecol Br Commonw       Date:  1968-08

3.  Less conservatism in the treatment of eclampsia.

Authors:  D Crichton; M Notelovitz; I Heller
Journal:  J Obstet Gynaecol Br Commonw       Date:  1968-10

4.  Aggressive toxemia management (preeclampsia and eclampsia).

Authors:  S F Rogers; C E Flowers; J A Alexander
Journal:  Obstet Gynecol       Date:  1969-05       Impact factor: 7.661

5.  Chlormethiazole in the prevention of eclampsia and the reduction of perinatal mortality.

Authors:  G M Duffus; M E Tunstall; R G Condie; I MacGillivray
Journal:  J Obstet Gynaecol Br Commonw       Date:  1969-07

6.  Diazepam (valium) as an adjunct in obstetric analgesia.

Authors:  C E Flowers; A J Rudolph; M M Desmond
Journal:  Obstet Gynecol       Date:  1969-07       Impact factor: 7.661

7.  The use of chlordiazepoxide in patients with severe pregnancy toxaemia. (A preliminary study of effects on the newborn infants).

Authors:  T H Lean; S S Ratnam; R Sivasamboo
Journal:  J Obstet Gynaecol Br Commonw       Date:  1968-08
  7 in total
  1 in total

Review 1.  Essential hypertension and pregnancy.

Authors:  R A Bear; N Erenrich
Journal:  Can Med Assoc J       Date:  1978-04-22       Impact factor: 8.262
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.